Familial Amyotrophic Lateral Sclerosis Mutants of Copper/Zinc Superoxide Dismutase Are Susceptible to Disulfide Reduction*

Ashutosh Tiwari and Lawrence J. HaywardDagger

From the Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01655

Received for publication, October 11, 2002, and in revised form, November 25, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We observed that 14 biologically metallated mutants of copper/zinc superoxide dismutase (SOD1) associated with familial amyotrophic lateral sclerosis all exhibited aberrantly accelerated mobility during partially denaturing PAGE and increased sensitivity to proteolytic digestion compared with wild type SOD1. Decreased metal binding site occupancy and exposure to the disulfide-reducing agents dithiothreitol, Tris(2-carboxyethyl)phosphine (TCEP), or reduced glutathione increased the fraction of anomalously migrating mutant SOD1 proteins. Furthermore, the incubation of mutant SOD1s with TCEP increased the accessibility to iodoacetamide of cysteine residues that normally participate in the formation of the intrasubunit disulfide bond (Cys-57 to Cys-146) or are buried within the core of the beta -barrel (Cys-6). SOD1 enzymes in spinal cord lysates from G85R and G93A mutant but not wild type SOD1 transgenic mice also exhibited abnormal vulnerability to TCEP, which exposed normally inaccessible cysteine residues to modification by maleimide conjugated to polyethylene glycol. These results implicate SOD1 destabilization under cellular disulfide-reducing conditions at physiological pH and temperature as a shared property that may be relevant to amyotrophic lateral sclerosis mutant neurotoxicity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Amyotrophic lateral sclerosis (ALS)1 is an age-dependent degenerative disorder of motor neurons in the spinal cord, brain stem, and brain (1). Approximately 10% of ALS cases are familial, and ~20% of these individuals inherit one of >90 autosomal dominant mutations in the gene encoding copper/zinc superoxide dismutase 1 (SOD1) (2).2

SOD1 is a 32-kDa homodimeric enzyme expressed predominantly in the cytosol that decreases the intracellular concentration of superoxide radicals (O<UP><SUB>2</SUB><SUP>&cjs1138;</SUP></UP>) by catalyzing their dismutation to O2 and H2O2. ALS-associated mutations of conserved residues throughout the protein impart a toxic property to the enzyme that appears unrelated to its normal dismutase activity (reviewed in Ref. 3). Whereas transgenic mice that overexpress mutant SOD1s consistently develop lethal motor neuron degeneration (4-8), mice that overexpress the wild type (WT) enzyme exhibit only subtle motor abnormalities (9). In addition, SOD1 knock-out mice are not susceptible to motor neuron loss unless following axonal injury (10).

Mutant SOD1 enzymes have been proposed to facilitate aberrant copper-mediated chemistry, disrupt protein recycling or chaperone function, form toxic aggregates, or induce organelle dysfunction or apoptosis (3, 11, 12), but the precise mechanism of specific motor neuron toxicity has not been elucidated. The observation that some mutant SOD1s exhibit accelerated turnover in vivo or increased proteolytic susceptibility compared with the WT enzyme (13-15) suggests that biologically significant perturbations of mutant SOD1 conformation occur. The induction of chaperone proteins that can protect cultured motor neurons from mutant SOD1 toxicity (16) and appear to associate with SOD1 mutants (17) provides further evidence that destabilization or unfolding of mutant SOD1s in vivo may be related to their toxicity.

We previously purified 14 different biologically metallated ALS mutant SOD1s and observed that one group of "WT-like" mutants (A4V, L38V, G41S, G72S, D76Y, D90A, G93A, and E133Delta ) bound copper in a fully active coordination environment remarkably similar to that of normal SOD1 despite causing a lethal phenotype (18). The other six "metal-binding region" mutants (H46R, H48Q, G85R, D124V, D125H, and S134N) were clearly distinguished from WT SOD1 according to decreased metal ion contents, altered visible absorption spectra, or decreased specific activities. In a further analysis by differential scanning calorimetry, we found that metal-binding region mutants generally exhibited a larger fraction of species that unfolded at low Tm values compared with those of the WT-like mutants and normal SOD1 (19). Although purified SOD1 mutants can lose in vitro metal ion binding specificity following partial denaturation at non-physiological pH (20), the retention of many native properties in the "as-isolated" WT-like mutants suggests that other influences may destabilize these SOD1 mutants in vivo.

Fully metallated bovine SOD1 is active in 4% SDS or 8 M urea (21) and melts in solution at temperatures above 90 °C (22). SOD1 also retains its dimeric quaternary structure upon exposure to 1% SDS in the absence of other denaturing stresses such as heat, urea, reducing agents, or EDTA (23-25). Structural properties of SOD1 that contribute to its extreme thermochemical stability include an eight-stranded beta -barrel motif, binding sites for copper and zinc ions, hydrophobic interactions associated with dimerization, and an unusual intrasubunit disulfide bond bridging a loop residue, Cys-57, and Cys-146 of the beta -barrel (24, 26). The loop that includes Cys-57 also strongly influences the conformation of Arg-143, which regulates steering of superoxide anion and reactivity of the copper ion via a local hydrogen bond network and the disulfide linkage to Cys-146 (27-29). Furthermore, portions of this loop contribute to the dimer interface and form the zinc ion binding site (26). Conservation of these structural features in all eukaryotic SOD1s suggests that conformational stability of the enzyme, in general, and the disulfide loop, in particular, is critical under physiological conditions.

The ratio of reduced (GSH) to oxidized glutathione ([GSH]/[oxidized glutathione]) of ~30-100:1 in the cytosol (30) normally inhibits the formation of disulfide linkages in cytosolic proteins (31), yet WT SOD1 maintains a strong disulfide bond. We hypothesized that the disulfide linkage in ALS-related SOD1 mutants could be vulnerable to cleavage under cellular reducing conditions, which might further destabilize even WT-like mutants. In this study, we correlated changes in electrophoretic mobility, cysteine accessibility to modifying reagents, and protease susceptibility upon incubation of purified SOD1 mutants with disulfide-reducing agents. We then compared sulfhydryl accessibility of WT versus mutant SOD1 proteins in tissue lysates from transgenic mice expressing WT, G85R, or G93A SOD1s under reducing conditions. Our findings suggest that SOD1 destabilization related to thiol-reducing influences in the spinal cord and brain may contribute to the toxicity of mutant SOD1 enzymes in familial ALS.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- All solutions were prepared using Milli-Q ultrapurified water (Millipore). EDTA was from Invitrogen; sodium and potassium phosphate (monobasic and dibasic), NaCl, and Tris base were from J. T. Baker; ascorbate, reduced glutathione (GSH), iodoacetamide, and human erythrocyte SOD1 were from Sigma; Tris(2-carboxyethyl)phosphine (TCEP) was from Pierce; NaOH was from Mallinckrodt; 1,4-dithiothreitol (DTT), SDS, HCl, methanol, and acetic acid were from EM Science; and Coomassie Brilliant Blue R-250 and bromphenol blue were from Bio-Rad. Formic acid and acetonitrile were from Fisher. Maleimide coupled to polyethylene glycol (Mal-PEG, molecular mass of 5 kDa) was from Shearwater Polymers (Huntsville, AL). Transgenic mice overexpressing either WT SOD1 (line B6SJL-TgN(SOD1)2Gur) or G93A SOD1 (line B6SJL-TgN(SOD1-G93A)1Gur) (4) were obtained from the Jackson Laboratory (Bar Harbor, ME), whereas those overexpressing G85R SOD1 (7) bred to homozygosity were provided by Dr. Zuoshang Xu.

SOD1 Protein Preparation-- Human WT or ALS-related mutant SOD1 enzymes (A4V, L38V, G41S, H46R, H48Q, G72S, D76Y, G85R, D90A, G93A, D124V, D125H, E133Delta , and S134N) containing biologically incorporated metal ions were isolated from a baculoviral expression system (18). Protein concentrations were estimated using a dimeric molar extinction coefficient at 280 nm of 10,800 M-1 cm-1 (32) or 13,800 M-1 cm-1 for D76Y SOD1 (33). The purity, molecular mass, and metal ion contents for copper and zinc were previously determined by mass spectrometry (18), and these same preparations were used in the present study unless otherwise indicated. The fully metallated enzyme is expected to contain 2 equivalents each of copper and zinc/dimer. The D76Y and E133Delta mutants each eluted as two distinct fractions during the final purification by ion exchange chromatography. A previous metal content analysis (in equivalents per dimer) revealed that fraction 1 for these mutants (D76Y-1: 0.58 Cu, 1.27 Zn; and E133Delta -1: 0.31 Cu, 1.26 Zn) contained more copper and zinc than did fraction 2 (D76Y-2: 0.36 Cu, 0.82 Zn; and E133Delta -2: 0.16 Cu, 0.84 Zn) (18).

Tissue Lysates-- Frozen mouse tissues (spinal cord, brain, brainstem, cerebellum, skeletal muscle, heart, kidney, or liver) were pooled from at least three animals and homogenized in ice-cold lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Nonidet P-40, 0.5% deoxycholate, and protease inhibitors ("CompleteTM EDTA-free," Roche Molecular Biochemicals) using a motorized pestle. Approximately 70 mg of tissue/ml lysis buffer was processed, and the lysate was centrifuged at 14,000 × g for 10 min at 4 °C. 0.2% SDS was added to the supernatant, and samples were stored at -80 °C. The protein concentration of the mouse spinal cord lysates was 2.8 ± 0.3 mg/ml, and the G85R tissue lysates ranged from 1.8-3.5 mg/ml as determined by the bicinchonic acid method (34).

Polyacrylamide Gel Electrophoresis-- Native PAGE of the purified SOD1 enzymes was performed as described previously (18). Partially denaturing PAGE was a modification of native PAGE in which 1) SDS was added to the protein sample and running buffer to favor migration based on the conformation-dependent degree of SDS binding and 2) samples were incubated with variable amounts of reducing agents or metal chelators prior to loading. The method differed from standard denaturing SDS-PAGE in that the amount of SDS was lower (0.1-0.4%), the amount of reducing agent during preincubation was variable, and the sample was not boiled. Proteins were separated on 15% polyacrylamide Tris-HCl gels (Bio-Rad) run at 12 V/cm (80 V total) for 2 h and stained with Coomassie Blue dye. The sample loading buffer for partially denaturing PAGE contained 62 mM Tris (pH 6.8), 10% glycerol, 0.05% bromphenol blue, and SDS, reducing agents, or chelators as specified. The standard gel running buffer contained 25 mM Tris (pH 8.3), 192 mM glycine, and 0.1% SDS. All protein size markers and samples run under denaturing conditions were boiled for 3 min in denaturing buffer (62 mM Tris (pH 6.8), 10% glycerol, 2% SDS, 5% beta -mercaptoethanol, and 0.01% bromphenol blue) before loading. For the partially denaturing gels (Figs. 1-3), the migration of dimeric WT SOD1 in the absence of disulfide-reducing agent was indicated by an arrow marked D. The migration of fully denatured and reduced monomeric WT SOD1 was indicated by an arrow marked M, which corresponded to the migration of a 21.5-kDa denatured marker protein. Gels were photographed with a Kodak DC120 digital camera, and the images were analyzed using Adobe Photoshop and Scion Image 4.0.2 software. Relative protein amounts were estimated by subtracting the background from the total signal for specific protein bands.

Mass Spectrometry-- The number of accessible cysteine residues in SOD1 variants was determined by the reaction of SOD1 proteins with iodoacetamide (35, 36) and detection of the number of adducts formed per subunit by electrospray ionization mass spectrometry (ESI-MS). WT or mutant SOD1 was incubated for 1-4 days in the absence or presence of 10 mM TCEP at 37 °C. Proteins were reacted with 5 mM iodoacetamide for 1 h before loading on an liquid chromatography/MS column (C18, 5 µm, 300-Å Vydac column, 1.0 mm, inner diameter × 15 mm) equilibrated with buffer A (1% formic acid, 2% acetonitrile) and were eluted by a gradient to buffer B (1% formic acid, 80% acetonitrile). Protein concentration during incubation was 150 µg/ml, and 3 µl was loaded/injection. ESI-MS was calibrated using porcine insulin (average mass = 5,734.60 Da).

Protease Susceptibility-- Digestion buffer contained 5 mM DTT, 150 mM NaCl, and 50 mM sodium phosphate at pH 7.0. WT and mutant SOD1 proteins were divided into aliquots of 3 µg each and incubated at 37 °C in digestion buffer alone for 6 h, in buffer containing 50 µg/ml proteinase K for 2 h, or in buffer containing 100 µg/ml trypsin for 6 h. The digestion was terminated by the addition of 10 mM phenylmethylsulfonyl fluoride, and the proteins were boiled immediately in denaturing buffer for 3 min before loading for standard SDS-PAGE. Proteins that remained intact were detected by Coomassie Blue staining.

Western Blot Detection of Accessible SOD1 Cysteines in Tissue Lysates-- Soluble tissue lysates containing 0.375 mg/ml total protein and protease inhibitors (Complete, EDTA-free, catalog number 1873580, Roche Diagnostics) were incubated for 12 h in the presence of 0, 0.3, 1.0, or 3.0 mM TCEP at 25 °C. Mal-PEG (molecular mass of 5 kDa) was then added to a final concentration of 3 mM for covalent modification of accessible cysteines for 1 h at 25 °C (37). The addition of Mal-PEG to accessible cysteines increases the subunit mass of SOD1 by ~5 kDa/modification. The reaction was competitively terminated upon addition of loading buffer for denaturing SDS-PAGE that contained 5% beta -mercaptoethanol (see above). For Western blot analysis, samples were immediately boiled at 100 °C for 3 min, separated by denaturing SDS-PAGE, and detected using a sheep polyclonal antibody to human SOD1 (catalog number 574597, Calbiochem) as described previously (18).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Both WT-like and Metal Binding Region ALS-related SOD1 Mutants Exhibited Aberrantly Increased Electrophoretic Mobility during Partially Denaturing SDS-PAGE-- Human and bovine WT SOD1s retain their homodimeric subunit association, activity, and metal binding in 1% SDS (21, 24, 25, 38). To compare the electrophoretic behavior of biologically metallated human WT and ALS mutant SOD1 variants (18) under partially denaturing conditions, we incubated these enzymes for 30 min with 0.4% SDS and increasing concentrations of the disulfide-reducing agent DTT without boiling prior to PAGE (Fig. 1).


View larger version (83K):
[in this window]
[in a new window]
 
Fig. 1.   ALS mutants were more susceptible than WT SOD1 to aberrant migration during partially denaturing SDS-PAGE. Human SOD1 proteins (3 µg/lane) isolated from erythrocytes (WT-C) or from an insect cell expression system (all others) were preincubated for 30 min at 37 °C in sample loading buffer consisting of 62 mM Tris (pH 6.8), 10% glycerol, 0.05% bromphenol blue, and the indicated amounts of SDS and DTT. Samples were not boiled, and the gel running buffer contained 0.1% SDS. Gels were stained with Coomassie Blue. The migration of dimeric WT SOD1 under these conditions is indicated by an arrow marked D, whereas the migration of denatured and reduced WT SOD1 monomer is shown by an arrow marked M. The metal contents of these proteins were determined previously by inductively coupled plasma mass spectrometry (18) and were (in equivalents per dimer) WT: 0.38 Cu, 1.37 Zn; A4V: 0.11 Cu, 1.36 Zn; L38V: 0.23 Cu, 1.32 Zn; G41S: 0.52 Cu, 1.35 Zn; H46R: 0.02 Cu, 0.07 Zn; H48Q: 0.63 Cu, 1.08 Zn; G72S: 0.74 Cu, 0.78 Zn; D76Y-1: 0.58 Cu, 1.27 Zn; D76Y-2: 0.36 Cu, 0.82 Zn; G85R: 0.00 Cu, 0.01 Zn; D90A: 0.34 Cu, 1.77 Zn; G93A: 0.45 Cu, 1.46 Zn; D124V: 0.01 Cu, 0.03 Zn; D125H: 0.09 Cu, 0.36 Zn; E133Delta -1: 0.31 Cu, 1.26 Zn; E133Delta -2: 0.16 Cu, 0.84 Zn; and S134N: 0.15 Cu, 0.33 Zn. The fully metallated enzyme is expected to contain 2 equivalents each of copper and zinc/dimer.

In the absence of DTT (first two lanes of each set), commercially available 32-kDa SOD1 holoenzyme from human erythrocytes (WT-C) migrated as a single band. We showed previously that our WT and WT-like as-isolated recombinant SOD1s typically contained <30% full copper site occupancy, most probably as a consequence of limited copper availability during overexpression in insect cells (18). Partially metallated recombinant WT SOD1 (WT) migrated as three distinct species under these conditions. The mobility of all WT species was considerably slowed compared with that of denatured SOD1 near the 21.5-kDa marker during standard SDS-PAGE (18), consistent with low SDS binding under these conditions. Upon exposure to 2-10 mM DTT, a small fraction of the WT SOD1 enzymes exhibited accelerated mobility near the mobility of the denatured WT monomer (Fig. 1, arrow marked M).

Four WT-like ALS mutants located at one pole of the beta -barrel (L38V, G41S, D90A, and G93A) contained amounts of copper and zinc ions comparable with as-isolated WT SOD1 (see Fig. 1 legend) and had normal specific activity (18). In contrast to WT SOD1, this group exhibited reproducible "smearing" when exposed only to 0.1% SDS in the gel-running buffer and in the absence of preincubation with SDS or DTT (Fig. 1, first lane in each set). Moreover, these mutants were distinguished from the WT enzyme by an accelerated mobility upon preincubation with DTT. This result suggested that these mutants were more susceptible than WT SOD1 to altered conformation or net charge induced by SDS or DTT.

Mutants that were partially deficient in either zinc (H48Q and G72S) or copper (A4V) compared with WT SOD1 (18) exhibited a component that migrated similarly to denatured WT SOD1 (Fig. 1, arrow marked M). In addition, two distinct fractions that differed only in metal occupancy were isolated by ion exchange chromatography for both the D76Y mutant and the single-residue deletion mutant E133Delta (18). The D76Y-2 and E133Delta -2 enzymes, which contained ~50-65% less copper and ~65% less zinc than did D76Y-1 and E133Delta -1 (18), were more susceptible to the effects of SDS and DTT on mobility.

Five ALS mutants with substitutions near the active site of SOD1 (H46R, G85R, D124V, D125H, and S134N) were severely copper- and zinc-deficient upon isolation from insect cells (18). These metal-binding region mutants exhibited nearly maximal mobility upon exposure to SDS either in the running buffer only (Fig. 1, first lane of each set) or after preincubation in 0.4% SDS (second lane of each set). This result suggested increased SDS binding to these mutants, possibly as a consequence of unfolding in this gel system, which was consistent with the established importance of metal binding to SOD1 for both chemical and thermal stability (19, 21, 22).

Exposure to EDTA Alone Did Not Mimic the Accelerated Mobility of SOD1 Mutants Caused by Disulfide-reducing Agents-- The results of Fig. 1 suggested that disulfide bond reduction or decreased metal occupancy or both contributed to faster migration of the mutant enzymes compared with WT SOD1. DTT could have either reduced the single intrasubunit disulfide bond (Cys-57 to Cys-146) (24) or chelated Zn(II) ions (Kd = 10-6.9 M at pH 7.4) or Cu(I) ions (Kd = 10-11.1 M at pH 7.4) (39). To determine whether the SOD1 mutants were sensitive to a strong metal ion chelator, we incubated the enzymes with EDTA in the absence or presence of DTT. Exposure to 20 mM EDTA alone did not mimic the gel mobility change induced by 2 mM DTT (Fig. 2A). However, the combination of 2 mM DTT and 20 mM EDTA altered the mobility of even the WT enzyme. This finding suggested but did not directly prove that reduction of the disulfide bond by DTT was important to facilitate metal ion chelation from SOD1 by either DTT or EDTA.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 2.   Incubation of SOD1s with EDTA alone did not mimic the effect of DTT. A, SDS-PAGE was performed as in Fig. 1 with the exception that the sample buffer contained 0.4% SDS and the indicated concentrations of EDTA and DTT. Proteins were incubated for 24 h at 25 °C prior to loading (3 µg/lane). SOD1 mutants were more susceptible than WT SOD1 to accelerated mobility after incubation with TCEP. B, SDS-PAGE was performed as in Fig. 1 with the exception that the sample buffer contained 0.1% SDS and the indicated concentration of TCEP. Proteins were incubated for 24 h at 37 °C before loading (3 µg/lane). The metal contents of these SOD1 preparations were (in equivalents per dimer) WT: 0.67 Cu, 1.62 Zn; A4V: 0.33 Cu, 1.81 Zn; L38V: 0.61 Cu, 1.91 Zn; and G93A: 0.63 Cu, 1.77 Zn.

To discern more clearly whether disulfide reduction was related to the observed SOD1 mobility changes, we incubated the SOD1 enzymes with TCEP, a highly stable reducing agent (40, 41). TCEP does not bind metal ions but specifically reduces disulfide bonds between protein regions (denoted by R and R') according to the following reaction.
(<UP>CH<SUB>2</SUB>CH<SUB>2</SUB>COOH</UP>)<SUB><UP>3</UP></SUB><UP>P: + RS–SR′ + H<SUB>2</SUB>O → </UP>(<UP>CH<SUB>2</SUB>CH<SUB>2</SUB>COOH<SUB>3</SUB>P = O</UP>

+RSH+R′SH

<UP><SC>Reaction</SC> 1</UP>
Fig. 2B shows that 2 mM TCEP was sufficient to fully shift the mobility of A4V SOD1 but had little effect on WT SOD1. Exposure to 10 mM TCEP for 24 h accelerated only ~25% WT, >60% G93A, and nearly all of A4V and L38V SOD1s as judged by Coomassie Blue staining (Fig. 2B). Similar results were obtained upon exposure of WT and mutant SOD1 to beta -mercaptoethanol (data not shown).

ALS-related SOD1 Mutants Were Susceptible to Incubation with GSH-- The cytosolic environment of the nervous system may expose proteins to strong reducing influences. For example, GSH is an abundant intracellular thiol (present at ~1-10 mM in neurons and glia) that can reduce disulfide bonds or be conjugated to accessible cysteine residues (42). Also, among other reducing agents that function as antioxidants by their free radical scavenging activity, ascorbate accumulates in neurons to ~3 mM (43). To determine whether the mobility of ALS mutants was sensitive to these agents, we incubated the purified enzymes with either GSH or ascorbate for 24 h at 37 °C and then analyzed the samples by PAGE. Fig. 3 demonstrates that while WT SOD1 was relatively resistant to 10-20 mM GSH, the mutant enzymes exhibited faster migration suggestive of unfolding or monomerization. In contrast, exposure to ascorbate (up to 100 mM) had no effect on mutant SOD1 mobilities (data not shown). Overall, the findings in Figs. 1-3 demonstrated strikingly distinct behavior during partially denaturing PAGE of purified WT and all of the 14 ALS-related mutants of SOD1 but did not precisely specify the origin of those differences.


View larger version (97K):
[in this window]
[in a new window]
 
Fig. 3.   SOD1 mutants were susceptible to disulfide reduction by GSH. SDS-PAGE was performed as in Fig. 1 with the exception that samples contained 0.1% SDS and the indicated concentration of GSH. Proteins were incubated for 24 h at 37 °C before loading (3 µg/lane). Metal contents of these SOD1 preparations were as shown in Fig. 2 for WT, A4V, L38V, and G93A, and they were as shown in Fig. 1 for H48Q and D90A proteins.

TCEP Preferentially Reduced the Disulfide Bond of SOD1 Mutants and Contributed to Increased Accessibility of a Cysteine Residue within the beta -Barrel Core-- We next correlated TCEP-induced changes in SOD1 mobility during native PAGE with altered accessibility of cysteine residues as determined by mass spectrometry. Fig. 4 shows the migration of WT and mutant SOD1 enzymes after native PAGE in the absence or presence of incubation with 10 mM TCEP for 1 day (left panel) or 4 days (right panel). Migration of the WT protein was not significantly altered after 1 day but was accelerated after 4 days, suggestive of increased net negative charge resulting from partial metal ion loss. In contrast, the mutant enzymes A4V, L38V, G85R, D90A, and G93A exhibited species that migrated more slowly on native PAGE after exposure to TCEP for 1-4 days. In the absence of significant conformational change, metal ion loss alone would be expected to accelerate rather than retard mobility of the mutants. For example, the as-isolated G85R mutant contained <5% metal occupancy (18) and migrated more rapidly than WT SOD1 before exposure to TCEP. These native PAGE results suggested that a conformational change related to either disulfide reduction by TCEP or metal ion loss impeded the mobility of the mutant but not WT enzymes.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   TCEP slowed the electrophoretic mobility of SOD1 mutants during native PAGE. Native PAGE of SOD1 proteins (5 µg/lane) following incubation for 1 day (left panel) or 4 days (right panel) at 37 °C in the absence or presence of 10 mM TCEP. C, carbonic anhydrase; L, lactalbumin; A, albumin.

To determine cysteine accessibility before and after exposure to TCEP, SOD1 proteins were incubated with 5 mM iodoacetamide, which reacts with each accessible sulfhydryl group to form an adduct that adds 57 Da to the subunit mass. Changes in the masses of WT and mutant SOD1 proteins following reaction with iodoacetamide were detected under denaturing conditions by ESI-MS. The deconvoluted spectra in Fig. 5 indicate the subunit masses of each resolved species, and the deduced number of modified cysteine residues is shown as a circled number for each peak. In the absence of incubation with TCEP, both the WT and mutant SOD1 proteins exhibited only a single prominent modification, which most probably corresponded to adduct formation at the surface-accessible Cys-111 residue.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   ALS SOD1 mutants exposed to TCEP exhibited greater accessibility of cysteine residues to alkylation by iodoacetamide. WT and mutant SOD1 proteins were exposed to 5 mM iodoacetamide for 1 h before loading on an liquid chromatography/MS column for ESI-MS under denaturing conditions. Shown are deconvoluted spectra with the masses of each protein subunit indicated. Circled numbers for each species indicate the number of cysteine residues alkylated by iodoacetamide as inferred from the measured masses (+57 Da change/modification). Protein concentration was 150 ng/µl, and 3 µl was loaded/injection. Metal contents of these preparations were as described in Fig. 1, and the masses of unmodified subunits were reported previously (18).

All 14 mutants were evaluated for cysteine accessibility by mass spectrometry, and all showed increased reactivity to iodoacetamide in the presence of TCEP. Following exposure to TCEP for 1 day, there was no change in cysteine accessibility for WT SOD1, but A4V, L38V, D76Y-1, D76Y-2, G85R, D125H, E133Delta -1, E133Delta -2, and S134N mutants exhibited species containing either three or four modified cysteines (Fig. 5). A total of three modified cysteines would be expected if the disulfide bond (Cys-57 to Cys-146) was cleaved, whereas all four cysteines of the subunit could be modified only if disulfide cleavage was accompanied by at least transient exposure of the side chain of Cys-6, which is normally buried in the interior of the beta -barrel. Similar results were also obtained for the mutants G41S, H46R, H48Q, G72S, and D124V after a 1-day incubation with TCEP (data not shown). The results for D76Y and E133Delta (Fig. 5) also clearly indicated that fractions containing lower metal occupancy were more susceptible to reaction with iodoacetamide. For the metal-depleted forms, the increased cysteine accessibility in Fig. 5 correlated with the observed mobility shifts in Fig. 1 and the protease susceptibility in Fig. 6.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 6.   Mutant SOD1s were more susceptible than WT SOD1 to digestion by proteinase K or trypsin in the presence of DTT. Digestion buffer contained 5 mM DTT, 150 mM NaCl, and 50 mM sodium phosphate at pH 7.0. SOD1 proteins (3 µg/lane) were incubated at 37 °C in buffer alone for 6 h (lane 1 for each set), buffer with 50 µg/ml proteinase K for 2 h (lane 2), or buffer with 100 µg/ml trypsin for 6 h (lane 3). The reactions were terminated by adding 10 mM phenylmethylsulfonyl fluoride, and samples were immediately boiled in loading buffer for denaturing SDS-PAGE followed by Coomassie Blue staining. Metal contents for WT, A4V, and L38V SOD1s were as shown in Fig. 2, and for the remaining preparations they were as shown in Fig. 1.

After exposure to TCEP for 4 days (Fig. 5), even the WT enzyme exhibited three modified cysteines indicative of disulfide cleavage by TCEP, whereas A4V, L38V, D90A, and G93A not only appeared disulfide-reduced but also exhibited species in which all four cysteines were modified. These results provided strong evidence that the mutant enzymes were more susceptible than WT to disulfide cleavage. Moreover, the reduction of the mutants but not WT SOD1 contributed to exposure of the buried Cys-6 residue and destabilization of the beta -barrel itself.

Mutant SOD1s Were All Susceptible to Digestion by Proteinase K or Trypsin in the Presence of DTT-- WT SOD1 and some ALS mutants expressed in COS-1 cells are resistant to digestion by proteinase K under non-reducing conditions (15). We hypothesized that a disulfide-reducing environment may partially unfold mutant but not WT SOD1 and thereby unmask a sensitivity to protease digestion. Therefore, we compared the fraction of purified WT or ALS mutant SOD1s remaining after exposure to either proteinase K or trypsin in the presence of DTT.

Standard denaturing SDS-PAGE in Fig. 6 revealed that the metal-binding region mutants (H46R, H48Q, G85R, D124V, D125H, and S134N) and the A4V mutant were completely digested by proteinase K or trypsin when incubated with 5 mM DTT at 37 °C. Other mutants at one pole of the beta -barrel (L38V, G41S, D90A, and G93A) or in loop regions (G72S, D76Y, and E133Delta ) exhibited partial digestion under these conditions, whereas the WT protein remained intact. D90A SOD1, which exhibited relative resistance to the effects of DTT (Fig. 1), TCEP (Figs. 2 and 5), or GSH (Fig. 3), was also the mutant most resistant to protease digestion (Fig. 6). However, as judged by Coomassie Blue staining, less than half of the D90A and G93A SOD1s remained after a 6-h digestion with trypsin.

We hypothesized that increased stability afforded by metal ion binding to SOD1 (19, 21, 22) could contribute to protease resistance despite the presence of a destabilizing mutation. To test this possibility, preparations of D76Y and E133Delta that differed only with respect to metal ion occupancy (18) were exposed to these proteases under reducing conditions (Fig. 6). The preparations with higher metal contents (D76Y-1 and E133Delta -1) were more resistant to proteolysis than were those with lower metal contents (D76Y-2 and E133Delta -2). The results of Fig. 6 also demonstrated that SDS, which was absent from the reaction buffer, was not required to unmask the protease sensitivity of the ALS mutant SOD1s upon exposure to DTT.

TCEP Increased SOD1 Cysteine Accessibility in Neural Tissue Lysates from ALS Mutant but Not WT SOD1 Transgenic Mice-- We next compared SOD1 cysteine reactivity in soluble lysates from transgenic mouse tissues expressing WT, G85R, or G93A SOD1s. Lysates were treated for 12 h with variable amounts of TCEP to simulate a reducing environment, and proteins were then covalently tagged at accessible cysteine residues with Mal-PEG. Reaction with Mal-PEG increased the subunit mass by ~5 kDa/modification, which was resolved by Western blot analysis (37). Fig. 7, left panel, shows that >90% SOD1 in spinal cord lysates from WT SOD1 transgenic mice was modified at a single cysteine residue, in agreement with the results obtained by mass spectrometry for the purified proteins in Fig. 5. Exposure of the WT lysate to TCEP for 12 h did not affect labeling by 3 mM Mal-PEG except at 3 mM TCEP, which inhibited the labeling reaction. In contrast, spinal cord lysates from G85R or G93A SOD1 mutant mice contained SOD1 species that were modified at 1-4 cysteine residues, and labeling at multiple residues was increased by exposure to TCEP (Fig. 7, left panel).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   SOD1 cysteines in tissue lysates from ALS transgenic mice exhibited increased accessibility to modification by Mal-PEG. Soluble tissue lysates were obtained from spinal cord (SC), brain (BN), cerebellum (CB), brain stem (BS), skeletal muscle (SK), heart (HT), kidney (K), and/or liver (L) tissues from WT (age 15 weeks), G85R (age 27 weeks), or G93A (age 15 weeks) human SOD1-expressing transgenic mice. Lysates were incubated with the indicated concentration of TCEP for 12 h at 25 °C, exposed to 3 mM Mal-PEG (MP) for 1 h, and subjected to SDS-PAGE (3 µg/lane) followed by Western blot detection with an anti-SOD1 antibody.

The middle and right panels of Fig. 7 shows that SOD1 in brain (BN), cerebellum (CB), brain stem (BS), skeletal muscle (SK), and heart (HT) tissues from G85R mice also exhibited susceptibility to modification by Mal-PEG at 2, 3, or all 4 cysteines in the presence of 1 mM TCEP. In contrast, only a small fraction of the total SOD1 in G85R mouse kidney (K) or liver (L) tissues was labeled by Mal-PEG, even in the presence of TCEP. Because even the surface Cys-111 was inefficiently labeled, this finding suggests the presence of an inhibitor of the labeling reaction in kidney and liver lysates. Overall, these results independently confirm the mass spectrometry results with the purified SOD1s and indicate that the presence of both an ALS mutation and a disulfide-reducing environment may decrease SOD1 stability.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The conformation and stability of ALS-related SOD1 mutants in affected tissues may be influenced directly by the mutant substitutions or indirectly as a consequence of disulfide bond reduction, decreased metal ion binding, monomerization, or other vulnerabilities under conditions in vivo. In this study, we correlated the effects of disulfide-reducing agents upon electrophoretic mobility, cysteine accessibility, and protease sensitivity among purified WT and ALS-related SOD1 variants of known metal ion content (18). We further demonstrated that G85R and G93A mutant SOD1s in transgenic mouse tissue lysates were susceptible to modification at normally inaccessible cysteine residues under reducing conditions.

Our initial observation that all 14 of the ALS mutants exhibited accelerated migration during partially denaturing PAGE (Figs. 1-3) indicated that ALS mutants share properties distinct from WT SOD1. To clarify the nature of those properties, we showed that the mutant proteins were more susceptible than WT SOD1 to disulfide reduction by TCEP (Fig. 5) and proteolysis in the presence of DTT (Fig. 6). Metal-binding region SOD1 mutants (H46R, G85R, D124V, D125H, and S134N) that were severely deficient in copper and zinc ions (18) exhibited the greatest increase in PAGE mobility (Fig. 1), increased reactivity to iodoacetamide in the presence of TCEP (Fig. 5), and greater susceptibility to proteolysis (Fig. 6). This behavior was consistent with the known importance of metal ion binding to SOD1 stability. However, even WT-like mutants (A4V, L38V, G41S, G72S, D76Y, D90A, G93A, and E133Delta ), which had more normal metal ion coordination and specific dismutase activity (18), could be distinguished from WT SOD1 under disulfide-reducing conditions (Figs. 1 and 5).

The large loop containing residues 49-84, which is anchored by the disulfide bond to the beta -barrel, not only composes part of the dimer interface but also forms the zinc binding site that links directly to the copper ion via His-63 (44). In addition, the backbone oxygen atoms of residues Cys-57 and Gly-61 in this loop form three hydrogen bonds that correctly orient the side chain of Arg-143, an important determinant of copper ion accessibility in SOD1 (27, 28, 45-48). These structural features increase the likelihood that disulfide reduction at Cys-57, and the disorder of this loop could facilitate partial unfolding, monomerization, metal ion loss, or altered reactivity of bound copper. Human SOD1 also contains two cysteine residues (Cys-6 and Cys-111) that increase the irreversibility of SOD1 thermal unfolding (49). The buried side chain of Cys-6, packed tightly within the interior of the beta -barrel, should remain inaccessible to solvent unless the SOD1 core is severely disrupted. For example, sulfhydryl reactivity of Cys-6 in bovine SOD1 occurs during exposure to 6 M guanidinium chloride but not 8 M urea (25). In contrast, the side chain of Cys-111 is exposed on the protein surface near the dimer interface and may be conjugated to GSH in vivo (50). Our mass spectrometry results (Fig. 5) suggest that increased susceptibility to disulfide reduction of SOD1 mutants also contributed to partial unfolding of the beta -barrel as indicated by accessibility of all four cysteine residues to modification by iodoacetamide. Consistent with these findings, Mal-PEG labeling of SOD1 at multiple cysteine residues was observed in tissue lysates from G85R and G93A but not WT SOD1 transgenic mice (Fig. 7).

SOD1 is unusual in its ability to form a stable intrasubunit disulfide bond in the reducing environment of the cytosol, and this property may also be important for proper folding of the enzyme (51, 52). We demonstrated that ALS-related SOD1 mutants were sensitive to physiological concentrations of glutathione (Fig. 3), the main cytosolic thiol-disulfide redox buffer. It is also possible that thiol-disulfide oxidoreductases of the thioredoxin and glutaredoxin pathways (53) could impair disulfide formation or stability during folding of the mutant SOD1 enzymes. In this regard, thioredoxin is up-regulated in erythrocytes of familial ALS patients (54), and its transcript is also increased ~6-fold in ALS spinal cord tissue (55), possibly as a defense against oxidative stress. The requirement to maintain cellular redox homeostasis and prevent the formation of non-native disulfide bonds thus might strongly influence the degree of mutant SOD1 misfolding or unfolding in specific tissues.

How might the susceptibility of mutant SOD1 enzymes to disulfide reduction relate to motor neuron toxicity in familial ALS? One possibility is that destabilization of the zinc-binding loop upon disulfide cleavage could promote selective zinc ion loss while retaining reactive copper ions at the active site. Zinc-deficient, copper-containing SOD1 is neurotoxic in vitro, possibly by a mechanism involving nitric oxide (56). Alternatively, disulfide reduction could alter copper ion reactivity by perturbing the position of Arg-143, which influences substrate selectivity or by creating a novel copper binding site upon exposure of free cysteine residues. On the other hand, disease progression in mutant SOD1 transgenic mice is not affected by genetic ablation of copper chaperone-dependent copper loading into SOD1 (57) or by expression of SOD1 mutants that severely disrupt the copper binding site (58). However, the toxicity of bound copper has not been completely excluded because unshielded copper ions may be toxic at even nanomolar concentrations (59).

Disulfide reduction of the ALS mutants may also contribute to toxicity by mechanisms independent of abnormal copper reactivity. For example, the exposure of hydrophobic residues or reactive cysteines could favor abnormal interactions of SOD1 with itself or with other cellular constituents. Mutant SOD1 can form insoluble protein complexes at early stages in G93A SOD1 transgenic mouse tissues and following proteasome inhibition in cultured cells (60). Similarly, a fraction of total mutant SOD1 in brain and spinal cord tissues from SOD1 mice forms high molecular weight complexes that accumulate with disease progression (61) and mouse tissues can exhibit thioflavin-S-positive inclusions (58). Oxidative stress may also be linked to the accumulation of mutant SOD1 either by decreased proteasome activity or by impaired degradation of oxidatively damaged SOD1 (62). An increased burden of partially unfolded SOD1 proteins or complexes could ultimately impair cellular chaperone capacity (16), perturb mitochondrial function (63), sequester anti-apoptotic factors (12), disrupt protein recycling, or impose an unsustainable metabolic cost to vulnerable tissues (reviewed in Ref. 3).

Our data suggest that cellular disulfide reducing influences at physiological temperature and pH are sufficient to convert relatively well folded WT-like SOD1 mutants (18) or less stable metal-binding region mutants (19) into more severely destabilized species. These non-native mutant forms might resemble the subset of highly unstable SOD1 C-terminal truncation mutants (15, 64), which also lack the disulfide bond consequent to deletion of Cys-146. Overall, these results implicate susceptibility to conformational destabilization of SOD1 by a cellular reducing environment as a shared property that may be relevant to ALS mutant neurotoxicity.

    ACKNOWLEDGEMENTS

We thank Drs. Robert H. Brown, Jr., C. Robert Matthews, Joan S. Valentine, Zuoshang Xu, and Jill Zitzewitz for insightful discussions and James E. Evans for assistance with mass spectrometry.

    FOOTNOTES

* This work was supported by the ALS Association (to L. J. H.), the National Institutes of Health Grant R01 NS44170 (to L. J. H.), and a Worcester Foundation for Biomedical Research Annual Research Fund Innovation Award (to L. J. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Neurology, University of Massachusetts Medical School, 55 Lake Ave., N., Worcester, MA 01655. Tel.: 508-334-4007; Fax: 508-334-2756; E-mail: Lawrence.Hayward@umassmed.edu.

Published, JBC Papers in Press, November 27, 2002, DOI 10.1074/jbc.M210419200

2 An updated list is posted at www.alsod.org.

    ABBREVIATIONS

The abbreviations used are: ALS, amyotrophic lateral sclerosis; DTT, 1,4-dithiothreitol; ESI-MS, electrospray ionization mass spectrometry; GSH, reduced glutathione; Mal-PEG, maleimide conjugated to polyethylene glycol; SOD1, copper/zinc superoxide dismutase; TCEP, Tris(2-carboxyethyl)phosphine; WT, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Rowland, L. P., and Shneider, N. A. (2001) N. Engl. J. Med. 344, 1688-1700[Free Full Text]
2. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H. X., et al.. (1993) Nature 362, 59-62[CrossRef][Medline] [Order article via Infotrieve]
3. Cleveland, D. W., and Rothstein, J. D. (2001) Nat. Rev. Neurosci. 2, 806-819[CrossRef][Medline] [Order article via Infotrieve]
4. Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H. X., et al.. (1994) Science 264, 1772-1775[Medline] [Order article via Infotrieve]
5. Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., and Price, D. L. (1995) Neuron 14, 1105-1116[Medline] [Order article via Infotrieve]
6. Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H., and Gordon, J. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 689-693[Abstract]
7. Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., and Cleveland, D. W. (1997) Neuron 18, 327-338[Medline] [Order article via Infotrieve]
8. Dal Canto, M. C., and Gurney, M. E. (1997) Acta Neuropathol. (Berlin) 93, 537-550[CrossRef][Medline] [Order article via Infotrieve]
9. Jaarsma, D., Haasdijk, E. D., Grashorn, J. A., Hawkins, R., van Duijn, W., Verspaget, H. W., London, J., and Holstege, J. C. (2000) Neurobiol. Dis. 7, 623-643[CrossRef][Medline] [Order article via Infotrieve]
10. Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., Jr., Scott, R. W., and Snider, W. D. (1996) Nat. Genet. 13, 43-47[Medline] [Order article via Infotrieve]
11. Brown, R. H., Jr. (1995) Curr. Opin. Neurobiol. 5, 841-846[CrossRef][Medline] [Order article via Infotrieve]
12. Okado-Matsumoto, A., and Fridovich, I. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 9010-9014[Abstract/Free Full Text]
13. Borchelt, D. R., Lee, M. K., Slunt, H. S., Guarnieri, M., Xu, Z. S., Wong, P. C., Brown, R. H., Jr., Price, D. L., Sisodia, S. S., and Cleveland, D. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8292-8296[Abstract]
14. Hoffman, E. K., Wilcox, H. M., Scott, R. W., and Siman, R. (1996) J. Neurol. Sci. 139, 15-20[CrossRef][Medline] [Order article via Infotrieve]
15. Ratovitski, T., Corson, L. B., Strain, J., Wong, P., Cleveland, D. W., Culotta, V. C., and Borchelt, D. R. (1999) Hum. Mol. Genet. 8, 1451-1460[Abstract/Free Full Text]
16. Bruening, W., Roy, J., Giasson, B., Figlewicz, D. A., Mushynski, W. E., and Durham, H. D. (1999) J. Neurochem. 72, 693-699[CrossRef][Medline] [Order article via Infotrieve]
17. Shinder, G. A., Lacourse, M. C., Minotti, S., and Durham, H. D. (2001) J. Biol. Chem. 276, 12791-12796[Abstract/Free Full Text]
18. Hayward, L. J., Rodriguez, J. A., Kim, J. W., Tiwari, A., Goto, J. J., Cabelli, D. E., Valentine, J. S., and Brown, R. H., Jr. (2002) J. Biol. Chem. 277, 15923-15931[Abstract/Free Full Text]
19. Rodriguez, J. A., Valentine, J. S., Eggers, D. K., Roe, J. A., Tiwari, A., Brown, R. H., Jr., and Hayward, L. J. (2002) J. Biol. Chem. 277, 15932-15937[Abstract/Free Full Text]
20. Goto, J. J., Zhu, H., Sanchez, R. J., Nersissian, A., Gralla, E. B., Valentine, J. S., and Cabelli, D. E. (2000) J. Biol. Chem. 275, 1007-1014[Abstract/Free Full Text]
21. Forman, H. J., and Fridovich, I. (1973) J. Biol. Chem. 248, 2645-2649[Abstract/Free Full Text]
22. Roe, J. A., Butler, A., Scholler, D. M., Valentine, J. S., Marky, L., and Breslauer, K. J. (1988) Biochemistry 27, 950-958[Medline] [Order article via Infotrieve]
23. Keele, B. B., Jr., McCord, J. M., and Fridovich, I. (1971) J. Biol. Chem. 246, 2875-2880[Abstract/Free Full Text]
24. Abernethy, J. L., Steinman, H. M., and Hill, R. L. (1974) J. Biol. Chem. 249, 7339-7347[Abstract/Free Full Text]
25. Malinowski, D. P., and Fridovich, I. (1979) Biochemistry 18, 5055-5060[Medline] [Order article via Infotrieve]
26. Bertini, I., Mangani, S., and Viezzoli, M. S. (1998) Adv. Inorg. Chem. 45, 127-250
27. Banci, L., Benedetto, M., Bertini, I., Del Conte, R., Piccioli, M., and Viezzoli, M. S. (1998) Biochemistry 37, 11780-11791[CrossRef][Medline] [Order article via Infotrieve]
28. Banci, L., Bertini, I., Del Conte, R., Fadin, R., Mangani, S., and Viezzoli, M. S. (1999) J. Biol. Inorg. Chem. 4, 795-803[CrossRef][Medline] [Order article via Infotrieve]
29. Banci, L., Bertini, I., Cramaro, F., Del Conte, R., and Viezzoli, M. S. (2002) Eur. J. Biochem. 269, 1905-1915[Abstract/Free Full Text]
30. Freedman, R. B. (1989) Cell 57, 1069-1072[Medline] [Order article via Infotrieve]
31. Raina, S., and Missiakas, D. (1997) Annu. Rev. Microbiol. 51, 179-202[CrossRef][Medline] [Order article via Infotrieve]
32. Goto, J. J., Gralla, E. B., Valentine, J. S., and Cabelli, D. E. (1998) J. Biol. Chem. 273, 30104-30109[Abstract/Free Full Text]
33. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) Protein Sci. 4, 2411-2423[Abstract/Free Full Text]
34. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85[Medline] [Order article via Infotrieve]
35. Lapko, V. N., Smith, D. L., and Smith, J. B. (2000) J. Mass Spectrom. 35, 572-575[CrossRef][Medline] [Order article via Infotrieve]
36. Yen, T. Y., Yan, H., and Macher, B. A. (2002) J. Mass Spectrom. 37, 15-30[CrossRef][Medline] [Order article via Infotrieve]
37. Makmura, L., Hamann, M., Areopagita, A., Furuta, S., Munoz, A., and Momand, J. (2001) Antioxid. Redox Signal. 3, 1105-1118[CrossRef][Medline] [Order article via Infotrieve]
38. Hartz, J. W., and Deutsch, H. F. (1972) J. Biol. Chem. 247, 7043-7050[Abstract/Free Full Text]
39. Krezel, A., Lesniak, W., Jezowska-Bojczuk, M., Mlynarz, P., Brasun, J., Kozlowski, H., and Bal, W. (2001) J. Inorg. Biochem. 84, 77-88[CrossRef][Medline] [Order article via Infotrieve]
40. Han, J. C., and Han, G. Y. (1994) Anal. Biochem. 220, 5-10[CrossRef][Medline] [Order article via Infotrieve]
41. Getz, E. B., Xiao, M., Chakrabarty, T., Cooke, R., and Selvin, P. R. (1999) Anal. Biochem. 273, 73-80[CrossRef][Medline] [Order article via Infotrieve]
42. Dringen, R. (2000) Prog. Neurobiol. 62, 649-671[CrossRef][Medline] [Order article via Infotrieve]
43. Rice, M. E. (2000) Trends Neurosci. 23, 209-216[CrossRef][Medline] [Order article via Infotrieve]
44. Tainer, J. A., Getzoff, E. D., Beem, K. M., Richardson, J. S., and Richardson, D. C. (1982) J. Mol. Biol. 160, 181-217[Medline] [Order article via Infotrieve]
45. Beyer, W. F., Jr., Fridovich, I., Mullenbach, G. T., and Hallewell, R. (1987) J. Biol. Chem. 262, 11182-11187[Abstract/Free Full Text]
46. Fisher, C. L., Cabelli, D. E., Tainer, J. A., Hallewell, R. A., and Getzoff, E. D. (1994) Proteins 19, 24-34[Medline] [Order article via Infotrieve]
47. Banci, L., Bertini, I., Cramaro, F., Del Conte, R., Rosato, A., and Viezzoli, M. S. (2000) Biochemistry 39, 9108-9118[CrossRef][Medline] [Order article via Infotrieve]
48. Lamb, A. L., Torres, A. S., O'Halloran, T. V., and Rosenzweig, A. C. (2001) Nat. Struct. Biol. 8, 751-755[CrossRef][Medline] [Order article via Infotrieve]
49. Lepock, J. R., Frey, H. E., and Hallewell, R. A. (1990) J. Biol. Chem. 265, 21612-21618[Abstract/Free Full Text]
50. Schinina, M. E., Carlini, P., Polticelli, F., Zappacosta, F., Bossa, F., and Calabrese, L. (1996) Eur. J. Biochem. 237, 433-439[Abstract]
51. Derman, A. I., Prinz, W. A., Belin, D., and Beckwith, J. (1993) Science 262, 1744-1747[Medline] [Order article via Infotrieve]
52. Battistoni, A., Mazzetti, A. P., and Rotilio, G. (1999) FEBS Lett. 443, 313-316[CrossRef][Medline] [Order article via Infotrieve]
53. Prinz, W. A., Aslund, F., Holmgren, A., and Beckwith, J. (1997) J. Biol. Chem. 272, 15661-15667[Abstract/Free Full Text]
54. Ogawa, Y., Kosaka, H., Nakanishi, T., Shimizu, A., Ohoi, N., Shouji, H., Yanagihara, T., and Sakoda, S. (1997) Biochem. Biophys. Res. Commun. 241, 251-257[CrossRef][Medline] [Order article via Infotrieve]
55. Malaspina, A., Kaushik, N., and de Belleroche, J. (2001) J. Neurochem. 77, 132-145[CrossRef][Medline] [Order article via Infotrieve]
56. Estevez, A. G., Crow, J. P., Sampson, J. B., Reiter, C., Zhuang, Y., Richardson, G. J., Tarpey, M. M., Barbeito, L., and Beckman, J. S. (1999) Science 286, 2498-2500[Abstract/Free Full Text]
57. Subramaniam, J. R., Lyons, W. E., Liu, J., Bartnikas, T. B., Rothstein, J., Price, D. L., Cleveland, D. W., Gitlin, J. D., and Wong, P. C. (2002) Nat. Neurosci. 5, 301-307[CrossRef][Medline] [Order article via Infotrieve]
58. Wang, J., Xu, G., Gonzales, V., Coonfield, M., Fromholt, D., Copeland, N. G., Jenkins, N. A., and Borchelt, D. R. (2002) Neurobiol. Dis. 10, 128-138[CrossRef][Medline] [Order article via Infotrieve]
59. Williams, R. J. P., and da Silva, J. J. R. F. (2000) Coord. Chem. Rev. 202, 247-348[CrossRef]
60. Johnston, J. A., Dalton, M. J., Gurney, M. E., and Kopito, R. R. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 12571-12576[Abstract/Free Full Text]
61. Wang, J., Xu, G., and Borchelt, D. R. (2002) Neurobiol. Dis. 9, 139-148[CrossRef][Medline] [Order article via Infotrieve]
62. Oeda, T., Shimohama, S., Kitagawa, N., Kohno, R., Imura, T., Shibasaki, H., and Ishii, N. (2001) Hum. Mol. Genet. 10, 2013-2023[Abstract/Free Full Text]
63. Kong, J., and Xu, Z. (1998) J. Neurosci. 18, 3241-3250[Abstract/Free Full Text]
64. Zu, J. S., Deng, H. X., Lo, T. P., Mitsumoto, H., Ahmed, M. S., Hung, W. Y., Cai, Z. J., Tainer, J. A., and Siddique, T. (1997) Neurogenetics 1, 65-71[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.